DiscoverCME in Minutes: Education in Rheumatology, Immunology, & Infectious DiseasesNicholas J. Silvestri, MD - Transforming Outcomes for Patients With gMG Through Enhanced Disease Control: A Focus on FcRn Antagonists
Nicholas J. Silvestri, MD - Transforming Outcomes for Patients With gMG Through Enhanced Disease Control: A Focus on FcRn Antagonists

Nicholas J. Silvestri, MD - Transforming Outcomes for Patients With gMG Through Enhanced Disease Control: A Focus on FcRn Antagonists

Update: 2025-06-12
Share

Description

Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Nicholas J. Silvestri, MD - Transforming Outcomes for Patients With gMG Through Enhanced Disease Control: A Focus on FcRn Antagonists

Nicholas J. Silvestri, MD - Transforming Outcomes for Patients With gMG Through Enhanced Disease Control: A Focus on FcRn Antagonists

Answers in CME